Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Expanded Access Use of Derazantinib for Patients With Locally Advanced, Inoperable or Metastatic iCCA Harbouring FGFR Genomic Alterations

Next Previous
Trial Profile

Expanded Access Use of Derazantinib for Patients With Locally Advanced, Inoperable or Metastatic iCCA Harbouring FGFR Genomic Alterations

Status: Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 12 May 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Derazantinib (Primary)
  • Indications Cholangiocarcinoma
  • Focus Expanded access; Therapeutic Use

    • Most Recent Events

    • 12 Oct 2020 Results of pooled analysis from two clinical studies and an expanded access program (n=23), presented in a Basilea Pharmaceutica Ltd media release.
    • 12 Oct 2020 According to a Basilea Pharmaceutica Ltd media release, results of pooled analysis from two clinical studies and an expanded access program was presented at the Molecular Analysis for Precision Oncology (MAP) Virtual Congress 2020 organized by the European Society for Medical Oncology (ESMO).
    • 17 Sep 2019 Status changed from planning to recruiting.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top